Strategic partnerships High-value collaboration potential with investors and strategic biotech partners exposed by Series A funding from Emerson Collective, Illumina Ventures, and Quan Capital, plus a notable industry partnership with MaxCyte, presenting opportunities to co-develop or co-finance B cell therapeutics and related platforms.

Platform expansion Strong B cell engineering platform across oncology, regenerative medicine, autoimmune disease, and recombinant antibody production suggests cross-industry targeting for contract research, custom cell engineering services, and licensing of proprietary B cell technologies to larger biopharma for accelerated product pipelines.

Key leadership Recent executive appointments of Chief Business Officer and Chief Technology Officer indicate strategic realignment and scaling of operations, signaling readiness for larger deals, alliance management, and enterprise-level partnerships with a clear point of contact for BD teams.

Funding runway Substantial Series A funding and ongoing investor interest imply a credible growth story and budget for partner-driven programs, enabling joint ventures, milestone-based collaborations, and sponsored research agreements with potential return on investment.

Specialized capabilities Expertise in B cell biology and engineering, with a focused technology stack and regulatory-friendly platforms, positions Walking Fish as a potential supplier of specialized cell engineering services, contract development cohorts, and proprietary tooling to support large biotech and pharma clients seeking novel B cell therapeutics.